{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "irregular", "bureauCode": ["026:00"], "contactPoint": {"@type": "vcard:Contact", "fn": "GeneLab Outreach", "hasEmail": "mailto:genelab-outreach@lists.nasa.gov"}, "description": "Accumulating data support the concept that ionizing radiation therapy (RT) has the potential to convert the tumor into an in situ individualized vaccine; however this potential is rarely realized by RT alone. Transforming growth factor  xce xb2 (TGF xce xb2) is an immunosuppressive cytokine that is activated by RT and inhibits the antigen-presenting function of dendritic cells and the differentiation of effector CD8+ T cells. Here we tested the hypothesis that TGF xce xb2 hinders the ability of RT to promote anti-tumor immunity. Development of tumor-specific immunity was examined in a pre-clinical model of metastatic breast cancer. Mice bearing established 4T1 mouse mammary carcinoma treated with pan-isoform specific TGF xce xb2 neutralizing antibody 1D11 showed significantly improved control of the irradiated tumor and non-irradiated metastases but no effect in the absence of RT. Notably whole tumor transcriptional analysis demonstrated the selective upregulation of genes associated with immune-mediated rejection only in tumors of mice treated with RT+TGF xce xb2 blockade. Mice treated with RT+TGF xce xb2 blockade exhibited cross-priming of CD8+ T cells producing IFN xce xb3 in response to three tumor-specific antigens in tumor-draining lymph nodes which was not evident for single modality treatment. Analysis of the immune infiltrate in mouse tumors showed a significant increase in CD4+ and CD8+ T cells only in mice treated with the combination of RT+TGF xce xb2 blockade. Depletion of CD4+ or CD8+ T cells abrogated the therapeutic benefit of RT+TGF xce xb2 blockade. These data identify TGF xce xb2 as a master inhibitor of the ability of RT to generate an in situ tumor vaccine which supports testing inhibition of TGF xce xb2 during radiotherapy to promote therapeutically effective anti-tumor immunity. We used genome-wide microarray to depict main biological processes responsibles for the therapeutic benefit of the combination ofTGF-beta blockade and local radiotherapy. To gain a more comprehensice protrait of the effects of RT and TGFbeta blockade on gene expressionin tumors we collected 4T1 tumors 4 days after completion of RT. Three tumors from each group were then subjected to RNA extraction and hybridization on affymetrix array.", "distribution": [{"@type": "dcat:Distribution", "description": "GeneLab Study Page", "downloadURL": "https://genelab-data.ndc.nasa.gov/genelab/accession/GLDS-160", "format": "HTML", "mediaType": "text/html", "title": "Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade"}], "identifier": "nasa_genelab_GLDS-160_t729-nms2", "issued": "2018-06-26", "keyword": ["array-scanning-protocol", "dose", "growth-protocol", "hybridization-protocol", "injection", "ionizing-radiation", "labelling-protocol", "normalization-data-transformation-protocol", "nucleic-acid-extraction-protocol", "p-gse61208-1", "p-gse61208-2", "p-gse61208-3", "p-gse61208-4", "p-gse61208-5", "p-gse61208-6", "p-gse61208-7", "sample-treatment-protocol"], "landingPage": "https://data.nasa.gov/dataset/gene-expression-data-from-4t1-irradiated-tumors-treated-with-tgfbeta-blockade", "modified": "2025-04-23", "programCode": ["026:005"], "publisher": {"@type": "org:Organization", "name": "National Aeronautics and Space Administration"}, "theme": ["Earth Science"], "title": "Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade"}